<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="320672">
  <stage>Registered</stage>
  <submitdate>6/10/2009</submitdate>
  <approvaldate>7/10/2009</approvaldate>
  <actrnumber>ACTRN12609000874213</actrnumber>
  <trial_identification>
    <studytitle>This is a randomised study to assess the safety and efficacy of a high dose vitamin D supplement compared to the standard vitamin D therapy in children.</studytitle>
    <scientifictitle>A study to assess the safety and efficacy of stoss therapy (high dose vitamin D supplement) compared to standard daily therapy in children diagnosed with simple vitamin D deficiency.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Vitamin D deficiency</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Other diet and nutrition disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>An oral intervention of 100,000 IU cholecalciferol weekly for 4 weeks with calcium supplementation 500mg daily for 4 weeks.</interventions>
    <comparator>An oral active control of 5000 IU cholecalciferol daily for 90 days with calcium supplementation 500mg daily for 90 days.</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Normalisation of 25-hydroxyvitamin D levels to &gt; 50 nmol/L by blood analysis.</outcome>
      <timepoint>At 12 weeks following randomisation.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Normalisation of alkaline phosphatase levels indicates restoration of bone mineral homeostasis by blood analysis.</outcome>
      <timepoint>At 12 weeks following randomisation.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety measure of urinary calcium: creatinine ratios.</outcome>
      <timepoint>At 4 and 12 weeks following randomisation.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety measure of other biochemical variables by blood analysis.</outcome>
      <timepoint>Following randomisation, blood analysis at 4 weeks to assess alkaline phosphatase concentrations and hypercalcaemia and at 12 weeks to assess for normalisation of mineral homeostasis.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Bone Age Assessment</outcome>
      <timepoint>At the baseline visit and only at 12 weeks to assess for resolution if rickets is present on x-ray.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adherence as assessed by return medication.</outcome>
      <timepoint>At 4 weeks following randomisation for the high dose group and at 12 weeks following randomisation for the low dose group.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Diagnosis of simple Vitamin D deficiency, &lt;50 nmol/L.
Be under the care of Endocrinologist and / or Refugee Clinic paediatrician</inclusivecriteria>
    <inclusiveminage>2</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>16</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pre-existing medical condition predisposing to Vitamin D deficiency e.g malabsorption.
Bone active medication e.g bisphosphonates. anticonvulsants.
No metabolic cause for rickets</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Consent obtained after diagnosis of simple Vitamin D deficiency (&lt;50 nmol/L) for randomise treatment for either the stoss (high dose therapy) or to the low dose standard treatment.
Concealment procedures using random number tables with equal numbers by an independent person.</concealment>
    <sequence>Simple randomisation by using random number tables.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/11/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>140</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>The Children's Hospital at Westmead</primarysponsorname>
    <primarysponsoraddress>Cnr Hainesworth Street and Hawkesbury Road Locked Bag 4001 Westmead NSW 2145</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>The Children's Hospital at Westmead</fundingname>
      <fundingaddress>Cnr Hainsworth Street and Hawkesbury Road. Locked Bag 4001 Westmead NSW 2145</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is a randomised study that will investigate the safety and effacy of stoss therapy (high dose weekly vitamin D supplementation for 4 weeks) compared to daily vitamin D for 3 months. The hypothesis is that stoss vitamin D therapy is a safe and effective treatment for vitamin D deficency. If proven safe and effective, stoss therapy would have significant advantages where therapy is shortened, thus improving compliance and ultimate recovery from Vitamin D deficiency.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Royal Alexander Hospital for Children Ethics Committee</ethicname>
      <ethicaddress>Cnr Hainesworth Street and Hawkesbury Road Westmead Locked Bag 4001 Westmead NSW 2145</ethicaddress>
      <ethicapprovaldate />
      <hrec>2006 / 107</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr. Craig Munns</name>
      <address>Genetic and Metabolic Bone Disorders
Institute of Endocrinology and Diabetes
Cnr Hainsworth Street and Hawkesbury Road Locked Bag 4001 Westmead NSW 2145</address>
      <phone>+61 2 98453200</phone>
      <fax>+61 2 98453170</fax>
      <email>craigm2@chw.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr. Craig Munns</name>
      <address>Genetic and Metabolic Bone Disorders
Institute of Endocrinology and Diabetes
Cnr Hainsworth Street and Hawkesbury Road Locked Bag 4001 Westmead NSW 2145</address>
      <phone>+61 2  98453200</phone>
      <fax>+61 2 98453170</fax>
      <email>craigm2@chw.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Lynne Foxall</name>
      <address>Genetic and Metabolic Bone Disorders
Institute of Endocrinology and Diabetes
Cnr Hainsworth Street and Hawkesbury Road Locked Bag 4001 Westmead NSW 2145</address>
      <phone>+61 2 9845 3179</phone>
      <fax>+61 2 98453170</fax>
      <email>lynnef@chw.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>